NCT06390956View on ClinicalTrials.gov

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2032

Conditions
Marginal Zone Lymphoma
Interventions
DRUG

Pirtobrutinib

Administered once daily as an oral medication.

Trial Locations (2)

63130

NOT_YET_RECRUITING

Washington University, St Louis

84112

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Utah

OTHER